Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics


Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $573.61 USD

1.69 (0.30%)

Updated Sep 29 4:00pm

Add REGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • REGN has a market capitalization of $60,847,937,976 -- more than approximately 96.83% of US stocks.
  • With a year-over-year growth in debt of 211.53%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 92.78% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Regeneron Pharmaceuticals Inc is reporting a growth rate of 55.02%; that's higher than 83.97% of US stocks.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, AMD, SNPS, MU, and CDNS.
  • Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.
REGN Daily Price Range
REGN 52-Week Price Range

REGN Stock Price Chart Technical Analysis Charts


REGN Price/Volume Stats

Current price $573.61 52-week high $664.64
Prev. close $571.92 52-week low $272.02
Day low $567.92 Volume 352,967
Day high $576.00 Avg. volume 1,130,374
50-day MA $600.39 Dividend yield N/A
200-day MA $520.34 Market Cap 61.03B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio


Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$573.61$844.58 48%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 53th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 96.23% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.66% of the free cash flow producing stocks we're observing.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.49% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%45%
1%46%
2%48%
3%49%
4%51%
5%52%

HRC, ENSG, RSCF, CBPO, and ACIU can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Atopic Dermatitis Market Size to 2026: Velite Pharmaceuticals, Galderma SA, Pfizer Inc, Fujisawa Healthcare, Inc., Dow, Regeneron Pharmaceuticals, Inc

The Atopic Dermatitis Market analysis report is a competent and deep analysis of the present situation and challenges. It also makes available analysis of market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2026. The market

OpenPR | September 28, 2020

3 Safe Coronavirus Stocks to Buy Ahead of a Market Crash

These companies may be near-term and long-term winners -- thanks to coronavirus work and solid product portfolios.

Yahoo | September 23, 2020

Merck’s Lung Cancer Drug Is a Blockbuster. Other Companies Are Starting to Challenge Its Dominance.

A coming rival will be Regeneron, whose presentation showed that its immuno-oncology drug Libtayo reduced deaths in lung cancer patients by 43%, compared with chemo, during an 11-month treatment.

Yahoo | September 22, 2020

Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

\- In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy

Yahoo | September 21, 2020

Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial

Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.The trial compared Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including those whose cancers had confirmed PD-L1 expression of ≥50%.Lung cancer is the leading cause of cancer death worldwide, with more than 2.2 million new cases expected globally in 2020. Approximately 85% of all lung cancers are NSCLC, and an estimated 25% to 30% of these cases are expected to test positive for PD-L1 in ≥50% of tumor cells.“In new analyses presented at ESMO, L...

Yahoo | September 21, 2020

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -4.81%
3-mo -5.84%
6-mo 15.01%
1-year 106.78%
3-year 28.29%
5-year 21.28%
YTD 52.77%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%
2015 32.33%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7925 seconds.